Healthcare shares are mixed in pre-market trade.
) is up 15.1% pre-market after it said the FDA does not expect to
take action on AMRN's supplemental new drug application (sNDA) for
the proposed ANCHOR indication labeling expansion for Vascepa
capsules on the December 20 Prescription Drug User Fee Act (PDUFA)
goal date because AMRN's request to re-instate the ANCHOR Special
Protocol Assessment agreement remains under consideration with the
FDA. No new PDUFA date was established.
Apricus Biosciences (
) is up 7.9% at $2.04 in the pre-market session after it said late
yesterday that the National Agency for Medicines and Health
Products Safety has granted national phase approval to Vitaros,
indicated for the treatment of patients with erectile
Vitaros is expected to become the first new and novel erectile
dysfunction product launched in nearly a decade. It will be
marketed in France by APRI's commercialization partner,
Copyright (C) 2013 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.